Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Aptevo Therapeutics ( Aptevo BioTherapeutics )
First received: October 7, 2008
Last updated: December 13, 2016
Last verified: December 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||February 2017|
|Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Martinowitz U, Shapiro A, Quon DV, Escobar M, Kempton C, Collins PW, Chowdary P, Makris M, Mannucci PM, Morfini M, Valentino LA, Gomperts E, Lee M. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 2012 Nov;18(6):881-7. doi: 10.1111/j.1365-2516.2012.02897.x.